AssetMark Inc
JBIO

AssetMark Inc’s Jade Biosciences JBIO Stock Holding History

AssetMark Inc’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14 Hold
1
– – ﹤0.01% 3425
2025
Q4 		$15 Hold
1
– – ﹤0.01% 3359
2025
Q3 		$9 Hold
1
– – ﹤0.01% 3174
2025
Q2 		$10 Buy
+1
New +$34 ﹤0.01% 2993

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AssetMark Inc's JBIO Position: Q1 2026 in Review

AssetMark Inc held its Jade Biosciences (JBIO) position steady in Q1 2026 at 1 share worth $14. The position accounts for ﹤0.01% of the portfolio, ranked #3425.

AssetMark Inc first reported a position in JBIO in Q2 2025 and has held it in 4 quarters since. The position peaked at $15 in Q4 2025. 120 funds tracked by Wall St. Rank hold JBIO as of Q1 2026.

  • AssetMark Inc held 1 share of Jade Biosciences worth $14 as of Q1 2026.
  • AssetMark Inc left its Jade Biosciences share count unchanged in Q1 2026.
  • Jade Biosciences made up ﹤0.01% of AssetMark Inc's portfolio in Q1 2026, its #3425 holding.
  • AssetMark Inc first reported a position in Jade Biosciences in Q2 2025 and has held it in 4 quarters since.
  • AssetMark Inc's Jade Biosciences position peaked at $15 in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2026.

Based on AssetMark Inc's 13F filing for Q1 2026, filed 6 May 2026.